Viz.ai, which uses AI to help medical professionals spot early signs of stroke, raises $50M Series B led by Greenoaks, bringing its total raised to ~$80M
Viz.ai, a healthcare startup that's using artificial intelligence (AI) to help medical professionals spot the early signs of stroke …
Context & Ripple Effects
This $50M Series B is the middle beat of Viz.ai's funding arc: it follows the $21M Series A Kleiner Perkins led in 2018 with GV participating, and precedes the $71M Series C that funded expansion beyond stroke into areas like cardiology, then a $100M Series D at a $1.2B valuation. At the time of this round, Viz.ai had raised about $80M total, making Greenoaks' lead a step-change in scale for an AI company whose product is diagnosis speed on time-sensitive conditions.
The round also sits inside a crowded niche: RapidAI, which applies AI to medical-scan analysis, was raising its own rounds in parallel and later pulled in a $75M Series C, while Evident Vascular emerged from stealth with AI-enabled intravascular imaging. Capital intensity in AI-assisted diagnostics was already visible before the 2019 close.
First-order effects
- Viz.ai gains roughly $50M from Greenoaks to scale its stroke-detection deployment across hospitals, roughly doubling its cumulative funding to about $80M and extending the Series A-era product roadmap well past initial pilots.
Second-order effects
- RapidAI's own fundraising cadence — a Series B in 2020 followed by a larger Series C — shows competitors matching Viz.ai round-for-round, forcing both vendors to spend on hospital sales coverage rather than compete purely on detection accuracy.
Third-order effects
- If the funding ladder holds, AI diagnostic software consolidates into multi-specialty platforms — Viz.ai's later stated move into cardiology being the template — leaving point-solution scan-analysis startups to be outspent or absorbed by the platform leaders.
The trend: Time-critical medical imaging AI is scaling through successive mega-rounds, with venture capital deciding which vendors become hospital-standard diagnostic infrastructure.